Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Sara Tolaney, MD, MPH (left), Margaret Haldoupis, RN, and Ian Krop, MD, PhD, plan clinical trials for breast cancer
We believe outstanding clinical care for patients with breast cancer is directly linked to an active program of breast cancer clinical trials. Our physician-scientists take the questions that arise in their clinical practices, answer them through clinical trials, and take this new knowledge back to the clinic where it can immediately benefit patients.
Breast cancer investigators are tackling cancer on multiple fronts, including immunotherapy and targeted treatments for the three subtypes: hormone receptor positive, HER2-positive, and triple-negative. This work includes primary tumors and metastatic cancer.
We offer our breast cancer patients access to more than 40 clinical trials at a time — many of which are changing the standard of care worldwide and are not available elsewhere. Our clinical trials focus on the types and phases of your disease so therapy can be targeted to your type of breast cancer.
Trial 20-068: MARGetuximab Or Trastuzumab (MARGOT): A phase II study comparing neoadjuvant paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab in patients with Stage II-III HER2-positive breast cancer Principal investigator: Ian E. Krop, MD, PhD
Trial 20-166: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC) Principal investigator: Sara M. Tolaney, MD, MPH
Trial 20-028: Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer Principal investigator: Elizabeth Ann Mittendorf, MD, PhD
Trial 16-466: A pilot study of changes in PD-L1 expression during preoperative treatment with nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer Principal investigator: Sara M. Tolaney, MD, MPH
Trial 17-512: A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer Principal investigator: Sara M. Tolaney, MD, MPH
Our breast cancer clinical trial finder provides an easy way to search for a clinical trial in breast cancer. Although this tool is currently geared for physicians, patients can benefit from it while a patient-friendly version is being developed.
At the Leading Edge of Breast Cancer Research: Immuno-OncologyLeaders of Dana-Farber’s Susan F. Smith Center for Women’s Cancers share updates on their groundbreaking work in immunotherapies and how this work is providing new treatments for breast cancer patients.
At the Leading Edge of Breast Cancer Research: Metastatic Breast CancerLeaders of Dana-Farber’s Susan F. Smith Center for Women’s Cancers share updates on their groundbreaking work in metastatic breast cancer and how this work is providing new treatments for breast cancer patients.
At the Leading Edge of Breast Cancer Prevention and Early DetectionLeaders of Dana-Farber’s Susan F. Smith Center for Women’s Cancers share updates on research to minimize and mitigate breast cancer risk and recurrence.
At the Susan F. Smith Center for Women’s Cancers, breast cancer patients are not only the beneficiaries of research advances; in a patient-centered approach, they help guide the research itself. The Breast Cancer Advocacy Group (BCAG), composed chiefly of breast cancer patients and survivors, provide a patient perspective to the Center's clinical investigators. The group reviews concepts and protocols for clinical trials from a patient’s perspective. For example, the advocates might recommend revisions to research questions so they more closely reflect the concerns of patients.
The advocates are also members of project teams for the Breast SPORE (Specialized Program of Research Excellence) from the National Cancer Institute, reviewing applications for institutional and SPORE-funded Career Development Awards, and working hand-in-hand with investigators to design research studies.
Learn more about breast cancer patient advocates, including how to become one.
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)
Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB TrialThis trial looks at a new breast cancer drug called tucatinib, combined with standard therapies. Results presented at SABCS 2019.